Your semaglutide monitoring panel explained: which blood tests matter and when

Step 1, baseline tests before your first dose

Before treatment begins, your prescriber will want a clinical picture of where you are starting from. A baseline panel typically covers renal function (eGFR and creatinine), liver enzymes (ALT and AST), fasting glucose or HbA1c, and a lipid profile including total cholesterol, LDL, HDL, and triglycerides. Blood pressure is recorded too. These numbers give your prescriber a reference point, if something shifts during treatment, it is only meaningful against a starting value.

Thyroid function is sometimes included, particularly if you have a history of thyroid disease. A raised TSH at baseline is relevant because medullary thyroid carcinoma and a personal or family history of MEN2 are contraindications to semaglutide, as detailed in the NHS patient information for semaglutide. Your prescriber will review all of this before confirming that treatment is appropriate.

At nume (at nume) sorry. At nume, baseline eligibility and medical history are assessed by a GPhC-registered Independent Prescriber who reads your consultation personally. A real clinician, on the day you submit.

Step 2, early checks after starting or increasing your dose

The first few weeks on semaglutide are when side effects are most likely to appear. Nausea, reduced appetite, and occasional vomiting are common; they tend to settle as the body adjusts. What the monitoring panel is watching for at this stage is whether any GI burden is affecting hydration or kidney function, and whether blood glucose (particularly in people who also have type 2 diabetes or prediabetes) is shifting in a meaningful direction.

If you are taking other medicines, your prescriber will also consider how semaglutide's effect on gastric emptying might influence their absorption. Oral contraceptives are a notable case, if you take the pill and are starting tirzepatide, different guidance applies, but for semaglutide the NHS England wraparound care framework notes no equivalent evidence of reduced pill effectiveness. Worth confirming with your own prescriber regardless.

A quick habit worth building: before each dose, check the pen storage log you keep in the fridge. If a pen has been left out longer than the SmPC allows, that is the moment to contact your prescriber, not after injecting. It takes under a minute and protects both efficacy and safety. Proper pen storage is covered on our Wegovy storage page if you want the detail.

Step 3 (ongoing monitoring and what the results can tell you

Once you are established on a maintenance dose, monitoring shifts to a rhythm) commonly every three to six months, though your prescriber sets the schedule based on your individual health profile. The lipid panel often shows improvement as weight falls: triglycerides tend to drop, and HDL-cholesterol can rise. These are the kinds of changes that make continued treatment clinically justifiable beyond simple weight numbers.

Liver enzymes are worth watching in people who had elevated ALT or AST at baseline, since semaglutide is now also being studied in metabolic liver disease contexts, though the weight-management licence and the newly authorised MASH indication are distinct, and your prescriber will be clear about which applies to you. Gallbladder health is another area of clinical interest, as rapid weight loss of any cause can increase the risk of gallstones; symptoms like right-upper-quadrant pain or nausea that does not follow the usual pattern should be mentioned promptly.

If you want a fuller picture of how semaglutide works and what the clinical trial data show, the semaglutide overview goes into both. For specifics on the 1mg and 2mg maintenance steps, this dose page and this one are the relevant reads. And if you are on or moving to the higher 7.2mg pen, the 7.2mg Wegovy page covers what the MHRA approved in April 2026.

Step 4, what happens if a result falls outside the expected range

Abnormal results do not automatically mean treatment stops. Context matters. A small rise in creatinine during a period of reduced fluid intake is different from a sustained decline in eGFR. Elevated liver enzymes that were normal at baseline and accompanied by right-sided pain need prompt investigation; the same enzymes mildly elevated in someone whose baseline was already borderline may simply warrant a repeat test in four weeks.

The NICE appraisal of semaglutide for weight management (NICE TA875) sets the framework within which NHS monitoring happens, and private prescribers follow the same clinical standards. The rule of thumb is that a prescriber who is genuinely monitoring you will be willing to pause, reduce, or stop treatment if the evidence points that way, not simply extend each prescription automatically.

You can read more about the full monitoring approach on our semaglutide monitoring page, and if cost is a factor in deciding whether private treatment is right for you, the Wegovy cost page sets out what a transparent private price should include. When you are ready to talk it through with a prescriber, the free consultation is the place to start.